Side-by-side · Research reference
GHRP-6vsLiraglutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 1Reviewed10/36 cited
BFDA-ApprovedVerified14/45 cited
GHRP-6
Hexapeptide GHRP · Strong appetite stimulant
SQ · Multiple sites · 1–3×/day
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
01Mechanism of Action
Parameter
GHRP-6
Liraglutide
Primary target
Ghrelin receptor (GHS-R1a)Bowers 1990
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Pathway
GHS-R1a → Gαq → Ca²⁺ → GH release; central appetite driveBowers 2002
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
Downstream effect
GH pulse + strong appetite stimulation; modest IGF-1 elevationBowers 2002
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Synthetic hexapeptide; first-generation GHRP from Bowers groupBowers 1990
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Antibody development
—
—
02Dosage Protocols
Parameter
GHRP-6
Liraglutide
Frequency
1–3× per day
Once daily, same time each day
Lower / starter dose
50 mcg per dose
—
Evidence basis
Phase 1 + clinical practiceBowers 1990
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Duration
8–12 weeks on / 4 off
Indefinite for chronic indication
Reconstitution
Bacteriostatic water
Pre-filled commercial pen (no reconstitution)
Timing
Pre-meal preferred for appetite support
Any time of day; consistent
Standard dose (weight, Saxenda)
—
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
Titration schedule
—
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
04Side Effects & Safety
Parameter
GHRP-6
Liraglutide
Hunger
Pronounced — defining feature vs ipamorelin
—
Cortisol elevation
Mild
—
Prolactin elevation
Mild
—
Injection site reaction
Mild
—
Cancer risk
Contraindicated in active malignancy
—
Pregnancy / OB
Avoid
Contraindicated
GI symptoms
—
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
Pancreatitis risk
—
Rare; discontinue if suspected
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
Hypoglycemia
—
Low risk as monotherapy; elevated with sulfonylureas / insulin
Heart rate
—
Modest ↑ resting HR (~2-3 bpm)
Absolute Contraindications
GHRP-6
- ·Active malignancy
- ·Pregnancy / breastfeeding
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Relative Contraindications
GHRP-6
- ·Severe insulin resistance (appetite-driven caloric load)
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
05Administration Protocol
Parameter
GHRP-6
Liraglutide
1. Reconstitution
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL.
Commercial pre-filled pen, no reconstitution required.
2. Injection site
SQ — abdomen. Rotate sites.
SQ — abdomen, thigh, or upper arm. Rotate sites.
3. Timing
Pre-meal for appetite support; pre-sleep for GH alignment.
Once daily, same time each day. Take with or without food.
4. Storage
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
5. Needle
29–31G, 4–8 mm insulin syringe.
Pen-supplied 32G needle.